

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

Anti-LRRK2/Dardarin, C-Terminus Antibody

RRID:AB_10675136

Type: Antibody

Proper Citation

Antibodies Incorporated Cat# 75-253, RRID:AB_10675136

Antibody Information

URL: http://antibodyregistry.org/AB_10675136

Proper Citation: Antibodies Incorporated Cat# 75-253, RRID:AB_10675136

Target Antigen: Dardarin/LRRK2, C-terminus

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: IB, ICC, IHC, KO, WB

Validation status: IF or IB (Pass), IB in brain (Pass), IHC in brain (Pass), KO (Pass)

This clone is associated with these products: purified (Antibodies Incorporated, Cat# 75-253, RRID:AB_10675136), supernatant (Antibodies Incorporated, Cat# 73-253, RRID:AB_10671178), hybridoma (UC Davis/NIH NeuroMab Facility, Cat# N241A/34, RRID:AB_2877351)

Antibody Name: Anti-LRRK2/Dardarin, C-Terminus Antibody

Description: This monoclonal targets Dardarin/LRRK2, C-terminus

Target Organism: rat, mouse, drosophila, human

Clone ID: N241A/34

Antibody ID: AB_10675136

Vendor: Antibodies Incorporated

Catalog Number: 75-253

Record Creation Time: 20250820T031229+0000

Record Last Update: 20250820T153824+0000

Ratings and Alerts

No rating or validation information has been found for Anti-LRRK2/Dardarin, C-Terminus Antibody.

No alerts have been found for Anti-LRRK2/Dardarin, C-Terminus Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen C, et al. (2025) Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons. bioRxiv : the preprint server for biology.

Chiang CY, et al. (2025) PPM1M, an LRRK2-counteracting, phosphoRab12-preferring phosphatase with a potential link to Parkinson's disease. Cell reports, 44(8), 116031.

Chiang CY, et al. (2025) PPM1M, a LRRK2-counteracting, phosphoRab12-preferring phosphatase with potential link to Parkinson's disease. bioRxiv : the preprint server for biology.

Pattanayak R, et al. (2024) 14-3-3 phosphorylation inhibits 14-3-3's ability to regulate LRRK2 kinase activity and toxicity. Human molecular genetics, 33(23), 2071.

Rinaldi C, et al. (2023) Dissecting the effects of GTPase and kinase domain mutations on LRRK2 endosomal localization and activity. Cell reports, 42(5), 112447.

Dhekne HS, et al. (2023) Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson's disease-linked LRRK2 kinase. eLife, 12.

Kalogeropoulou AF, et al. (2022) Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding. The Biochemical journal, 479(17), 1759.

Malik AU, et al. (2022) PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain. The Biochemical journal, 479(18), 1941.